Biocon's Revenue Could Hit $1 Bn In 4 Years, Says Kiran Mazumdar-Shaw

In a tie-up with U.S. generic drugmaker Mylan NV, the Bengaluru-based biopharmaceutical firm has five biosimilar products - almost identical copies of original drugs - entering global regulatory approval stage which is expected to take about 18-20 months

Teva May Move Court Against Dr Reddy's For Patent Infringement

Ranbaxy Halts Generic Lipitor Prodn After Recall